Preliminary assessment of the safety and immunogenicity of a new CTXΦ- negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate

Infection and Immunity

Volumn 67, Issue 2, 1999, Pages 539-545

  Benítez, Jorge A ^a,e   García, Luis ^b   Silva, Anisia ^c   García, Hilda ^b   Fando, Rafael ^a   Cedré, Barbara ^b   Pérez, Antonio ^d   Campos, Javier ^a   Rodríguez, Boris L ^a   Pérez, José L ^b   Valmaseda, Tania ^b   Pérez, Oliver ^b   Pérez, Alberto ^b   Ramírez, Margarita ^d   Ledón, Talena ^a   Jidy, Manuel Díaz ^d   Lastre, Miriam ^b   Bravo, Laura ^d   Sierra, Gustavo ^b  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Instituto Finlay   (Cuba)

^c UNIVERSITY OF HAVANA   (Cuba)

^d INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^e University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN A; PLACEBO; PROTEINASE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FECES ANALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIBRIO CHOLERAE;

EID: 0345004860     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.2.539-545.1999     Document Type: Article

References (42)

1. Benenson, A., S. Saad, and A. Mosley. 1968. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull. W. H. O. 38:277-285.
2. Benitez, J. A., R. G. Spelbrink, A. Silva, T. E. Phillips, C. M. Stanley, M. Boesman-Finkelstein, and R. A. Finkelstein. 1997. Adherence of Vibrio cholerae to cultured differentiated human intestinal cells: an in vitro colonization model. Infect. Immun. 65:3474-3477.
3. Benitez, J. A., A. Silva, B. L. Rodríguez, R. Fando, J. Campos, A. Robert, H. Garcia, L. Garcia, J. L. Perez, R. Oliva, C. A. Torres, and T. Ledon. 1996. Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains. Arch. Med. Res. 27: 275-283.
4. Campos, J., R. Fando, A. Silva, B. L. Rodriguez, and J. A. Benitez. 1998. Replicating function of the RS1 element associated with Vibrio cholerae CTXΦ prophage. FEMS Microhiol. Lett. 164:141-147.
5. Czerkinsky, C., L.-A. Nillson, H. Nygren, O. Ouchterlony, and A. Tarkowski. 1983. A solid-phase enzyme-linked immunospot (ELISPOT) assay for the enumeration of specific antibody secreting cells. J. Immunol. Methods 65: 109-121.
6. Falero, G., B. L. Rodriguez, T. Valmaseda, M. E. Perez, J. A. Benitez, and G. Sierra. 1998. Production and characterization of a new monoclonal antibody against mannose-sensitive hemagglutinin of Vibrio cholerae. Hybridoma 17: 63-67.
7. Fando, R., J. L. Pérez, B. L. Rodríguez, J. Campos, A. Robert, L. García, A. Silva, and J. A. Benitez. 1997. Promoter activities in Vibrio cholerae ctxΦ prophage. Infect. Immun. 65:1561-1565.
8. Finkelstein, R. A. 1992. Cholera enterotoxin (choleragen): a historical perspective, p. 155-187. In D. Barua and W. B. Greenough (ed.). Cholera. Plenum Medical Book Company, New York, N.Y.
9. Finkelstein, R. A., M. Boesman-Finkelstein, Y. Chang, and C. Häse. 1992. Vibrio cholerae hemagglutinin/protease, colonial variation, virulence, and detachment. Infect. Immun. 60:472-478.
10. Formal, S. B., D. Kundel, H. Schneider, N. Kunev, and H. Sprinz. 1961. Studies with Vibrio cholerae in ligated loops of the rabbit intestine. Br. J. Exp. Pathol. 42:504-510.
11. Gotuzzo, E., B. Butron, C. Seas, M. Penny, R. Ruiz, G. Losonsky, C. F. Lanata, S. S. Wasserman, E. Salazar, J. B. Kaper, S. Cryz, and M. M. Levine. 1993. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61:3994-3997.
12. Häse, C., and R. A. Finkelstein. 1993. Bacterial extracellular zinc-containing metalloproteases. Microbiol. Rev. 57:823-837.
13. Herrington, D. A., R. H. Hall, G. A. Losonsky, J. J. Mekalanos, R. K. Taylor, and M. M. Levine. 1988. Toxin, the toxin co-regulated pili and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J. Exp. Med. 168:1487-1492.
14. Holmgren, J., J. Osek, and A.-M. Svennerholm. 1994. Protective oral cholera vaccine based on a combination of cholera toxin B subunit and inactivated cholera vibrios, p. 415-424. In I. K. Wachsmuth, P. A. Blake, and Ø. Olsvik (ed.), Vibrio cholerae and cholera: molecular to global perspectives. American Society for Microbiology, Washington, D.C.
15. Ichinose, Y., M. Ehara, T. Honda, and T. Miwatani. 1994. The effect on enterotoxicity of protease purified from Vibrio cholerae. FEMS Microbiol. Lett. 115:265-272.
16. Iwanaga, M., K. Yamamoto, N. Higa, Y. Ichinose, N. Nakasone, and M. Tanabe. 1986. Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol. Immunol. 30:1075-1083.
17. Kaper, J. B., G. Morris, Jr., and M. M. Levine. 1995. Cholera. Clin. Microbiol. Rev. 8:48-86.
18. Kenner, J. R., T. S. Coster, D. N. Taylor, A. F. Trofa, M. Barrera-Oro, T. Hyman, J. M. Adams, D. T. Beattie, K. P. Killeen, D. R. Spriggs, J. J. Mekalanos, and J. C. Sadoff. 1995. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis. 172:1126-1129.
19. Ketley, J. M., J. B. Kaper, J. B. Herrington, D. A. Losonsky, and M. M. Levine. 1990. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103. Infect. Immun. 58:1481-1484.
20. Kimsey, H., and M. Waldor. 1997. Heteroimmunity amongst CTXΦ, p. 42-46. In Abstracts of the 33rd Joint Conference on Cholera and Related Diarrheal Disease, Clearwater Beach, Fla.
21. Kotloff, K. L., S. S. Wasserman, S. O'Donnell, G. A. Losonsky, S. J. Cryz, and M. M. Levine. 1992. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect. Immun. 60:4430-4432.
22. Kumar, K. K., R. Srivastava, V. B. Sinha, J. Michalski, J. B. Kaper, and B. S. Srivastava. 1994. recA mutations reduce adherence and colonization by classical and El Tor strains of Vibrio cholerae. Microbiology 140:1217-1222.
23. Levine, M. M., and C. O. Tacket. 1994. Recombinant live cholera vaccines, p. 395-414. In I. K. Wachsmuth, P. A. Blake, and Ø. Olsvik (ed.), Vibrio cholerae and cholera: molecular to global perspectives. American Society for Microbiology, Washington, D.C.
24. Levine, M. M., and J. B. Kaper. 1993. Live oral vaccines against cholera: an update. Vaccine 11:107-212.
25. Levine, M. M., J. B. Kaper, D. Herrington, G. Losonsky, J. Glenn Morris, M. I. Clements, R. E. Black, B. Tall, and R. Hall. 1988. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect. Immun. 56:161-167.
26. Levine, M. M., J. B. Kaper, D. Herrington, J. Ketley, G. Losonsky, C. O. Tacket, B. Tall, and S. Cryz. 1998. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD103 and CVD103-HgR. Lancet ii:467-470.
27. Lycke, N. 1986. Cholera toxin and the intestinal immune response. Experimental study at the single cell level. Ph.D. thesis. University of Göteborg, Göteborg, Sweden.
28. Mekalanos, J. J., M. K. Waldor, C. L. Gardel, T. S. Coster, J. Kenner, K. P. Killeen, D. T. Beattie, A. Trofa, D. N. Taylor, and J. C. Sadoff. 1995. Live cholera vaccines: perspectives on their construction and safety. Bull. Inst. Pasteur 93:255-262.
29. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
30. Robert, A., A. Silva, J. A. Benitez, B. L. Rodriguez, R. Fando, J. Campos, D. K. Sengupta, M. Boesman-Finkelstein, and R. A. Finkelstein. 1996. Tagging a Vibrio cholerae El Tor candidate vaccine strain by disruption of its hemagglutinin/protease gene using a novel reporter enzyme, Clostridium thermocellum endoglucanase A. Vaccine 14:1517-1522.
31. Siebers, A., and B. B. Finlay. 1996. M cells and the pathogenesis of mucosal and systemic infection. Trends Microbiol. 4:22-29.
32. Silva, T. M. J., M. A. Schleupner, C. O. Tacket, T. S. Steiner, J. B. Kaper, R. Edelman, and R. L. Guerrant. 1996. New evidence for an inflammatory component in diarrhea by selected new, live attenuated cholera vaccines and by El Tor and O139 Vibrio cholerae. Infect. Immun. 64:2362-2364.
33. Simon, R., U. Priefer, and A. Puhler. 1983. A broad host-range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram-negative bacteria. Bio/Technology 1:784-791.
34. Su-Arehawaratana, P., P. Singharaj, D. N. Taylor, C. Hoge, A. Trofa, K. Kuvanont, S. Migasena, P. Pitisuttitham, Y. L. Lim, G. Losonsky, J. B. Kaper, S. S. Wasserman, S. Cryz, P. Echeverria, and M. M. Levine. 1992. Safety and immunogenicity of different immunization regimens of CVD103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165:1042-1048.
35. Svennerholm, A. M., D. A. Sack, J. Holmgren, and P. K. Bardhan. 1982. Intestinal antibody response after immunization with cholera B subunit. Lancet i:305-308.
36. Svennerholm, A. M., G. Jonson, and J. Holmgren. 1994. Immunity to Vibrio cholerae, p. 257-272. In I. K. Wachsmuth, P. A. Blake, and Ø. Olsvik (ed.), Vibrio cholerae and cholera: molecular to global perspectives. American Society for Microbiology, Washington, D.C.
37. Tacket, C. O., G. Losonsky, J. P. Nataro, S. J. Cryz, R. Edelman, A. Fasano, J. Michalski, J. B. Kaper, and M. M. Levine. 1993. Safety and immunogenicity of live oral cholera vaccine candidate CVD110, a ΔctxA Δzot Δace derivative of El Tor Ogawa Vibrio cholerae. J. Infect. Dis. 168:1536-1540.
38. Taylor, D. N., K. P. Killeen, D. C. Hack, J. R. Kenner, T. S. Coster, D. T. Beattie, J. Ezzell, T. Hyman, A. Trofa, M. J. Sjogren, A. Friedlander, J. J. Mekalanos, and J. C. Sadoff. 1994. Development of a live, oral, attenuated vaccine against El Tor cholera. J. Infect. Dis. 170:1518-1523.
39. Thelin, K. H., and R. K. Taylor. 1996. Toxin coregulated pilus, but not mannose-sensitive hemagglutinin is required for colonization by Vibrio cholerae O1 El Tor and O139 strains. Infect. Immun. 64:2853-2856.
40. Waldor, M. K., and J. J. Mekalanos. 1996. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 272:1910-1914.
41. Waldor, M. K., E. J. Rubin, G. D. N. Pearson, H. Kimsey, and J. J. Mekalanos. 1997. Regulation, replication, and integration functions of the Vibrio cholerae CTXΦ are encoded by region RS2. Mol. Microbiol. 24:917-926.
42. Wu, Z., D. Milton, P. Nybom, A. Sjö, and K.-E. Magnusson. 1996. Vibrio cholerae hemagglutinin/protease (HA/protease) causes morphological changes in cultured epithelial cells and perturbs their paracellular barrier function. Microb. Pathog. 21:111-123.